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non-small cell lung cancer treated with
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Abstract
Background/aim: mmune checkpoint inhibition (CPI) has an increasing impact in the multimodal treatment of
locally advanced non-small cell lung cancer (LA-NSCLC). Increasing evidence suggests treatment outcome
depending on tumor cell PD-L1 expression. The purpose of this retrospective study was to investigate the
prognostic value of PD-L1 expression on tumor cells in combination with CD8+ tumor stroma-infiltrating
lymphocyte (TIL) density in inoperable LA-NSCLC treated with concurrent chemoradiotherapy (CRT).
Patients and method: We retrospectively assessed clinical characteristics and initial tumor biopsy samples of 31
inoperable LA-NSCLC patients treated with concurrent CRT. Prognostic impact of tumor cell PD-L1 expression (0%
versus ≥1%) and CD8+ TIL density (0–40% vs. 41–100%) for local control, progression-free (PFS) and overall survival
(OS) as well as correlations with clinicopathological features were evaluated.
Results: Median OS was 14months (range: 3–167months). The OS rates at 1- and 2 years were 68 and 20%. Local control
of the entire cohort at 1 and 2 years were 74 and 61%. Median PFS, 1-year and 2-year PFS were 13 ± 1.4months, 58 and
19%. PD-L1 expression < 1% on tumor cells was associated with improved OS, PFS and local control in patients treated with
concurrent CRT. Univariate analysis showed a trend towards improved OS and local control in patients with low CD8+ TIL
density. Evaluation of Tumor Immunity in the MicroEnvironment (TIME) appears to be an independent prognostic factor for
local control, PFS and OS. The longest and shortest OS were achieved in patients with type I (PD-L1neg/CD8low) and type IV
(PD-L1pos/CD8low) tumors (median OS: 57 ± 37 vs. 10 ± 5months, p= 0.05), respectively.
Conclusion: Assessment of PD-L1 expression on tumor cells in combination with CD8+ TIL density can be a predictive
biomarker in patients with inoperable LA-NSCLC treated with concurrent CRT.
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Introduction
Lung cancer remains the leading cause of cancer-related mor-
tality worldwide [1–3]. Locally-advanced non-small cell lung
cancer (LA-NSCLC) represents as a heterogeneous disease in-
cluding large tumor volume, extensive lymph node involve-
ment, tumor-related atelectasis and infiltration of the thoracic
wall, mediastinum and spine [4–6]. The majority of LA-
NSCLC patients are inoperable and multimodal approaches
are considered a cornerstone of treatment [7–10]. Historically,
administering platinum-based chemotherapy concurrently to
thoracic irradiation resulted in modest improvements of local
control, metastasis-free and overall survival (OS) compared to
radiotherapy alone [11, 12]. In the last years, the role of im-
mune checkpoint inhibition (CPI) in the multimodal treat-
ment of LA-NSCLC has evolved [9, 12]. In 2015, the first
programmed cell death protein 1 (PD-1) inhibitor (nivolumab)
was approved by the Food and Drug Administration (FDA)
for advanced or metastatic NSCLC in the second-line setting
following progression during or after platinum-based chemo-
therapy [13, 14]. Subsequently in 2016, the FDA approved
monotherapy with the PD-1 inhibitor pembrolizumab in the
first-line setting for patients with metastatic NSCLC with pro-
grammed cell death 1 ligand 1 (PD-L1) Tumor Proportion
Score (TPS)≥ 50% and expanded the indication in April 2019
based on the results of the KEYNOTE-042 trial for the first-
line treatment of patients with stage III patients who are not
candidates for surgical resection or definitive CRT or meta-
static NSCLC with TPS≥ 1% determined by an FDA-
approved test. Patients’ tumors had no Epidermal Growth
Factor Receptor (EGFR) or Anaplastic lymphoma kinase
(ALK) genomic aberrations [15, 16].
The addition of pembrolizumab to chemotherapy re-
sulted in significantly higher rates of response and lon-
ger PFS than chemotherapy alone in a phase 2 cohort of
the KEYNOTE-021 trial [17] and the FDA granted accel-
erated approval in May, 2017. CPI and chemotherapy
combination therapy was also tested in the first-line set-
ting in the KEYNOTE-189 and KEYNOTE-407 trials for
metastatic nonsquamous NSCLC without sensitizing
EGFR or ALK mutations and squamous NSCLC, re-
spectively [18, 19]. Both studies reporting significantly
improved OS and progression-free survival (PFS) than
chemotherapy alone. Furthermore, the IMpower150 trial
demonstrated superior PFS and OS for carboplatin/pac-
litaxel, bevacizumab and the PD-L1 blocking antibody
atezolizumab vs. carboplatin/paclitaxel and bevacizumab
in metastatic nonsquamous NSCLC, regardless of PD-L1
status and EGFR or ALK genetic alteration status [20].
Both combinations have been approved by the FDA.
Vis-à-vis stage III NSCLC, as a result of the PACIFIC trial,
maintenance treatment with PD-L1 inhibitor durvalumab
after successful completion of platinum-based concurrent
chemoradiotherapy (CRT) has demonstrated significantly
improved PFS and OS and became a new standard of care in
inoperable stage III NSCLC [8, 9]. Currently, predictors for
response to CPI are unclear and potential biomarkers are
under investigation including PD-L1 expression of tumor
cells, tumor-infiltrating lymphocytes (TIL), T-effector-
interferon-γ-associated gene expression and tumor muta-
tional burden (TMB) [21–23]. High mutation load has been
shown to correlate with an immunogenic tumor microenvir-
onment with increased expression of tumor-specific neo-
antigens that can be targeted by activated immune cells e.g.
cytotoxic CD8+ TILs [24, 25].
Considering the importance of PD-L1 expression on
tumor cells and CD8 TIL density in defining the tumor
immune microenvironment, we aimed to study PD-L1
expression alone and in combination with CD8 TIL
density with relation to clinicopathologic characteristics
and survival in patients treated with concurrent CRT.
Methods
Patients and samples
This study included 31 patients who received concurrent
CRT for locally advanced or metastatic NSCLC. From
their medical records, we retrieved patients’ clinical data,
such as sex, age, histologic type and grading, pack years
and TNM stage (using the 8th UICC TNM Staging Sys-
tem of lung cancer). Evaluation of EGFR/ALK genomic
aberrations was performed in nonsquamous metastatic
patients and was negative. All patients were closely
followed-up according to an in-house protocol - every 3
months in the first 2 years, every 6months up to 5 years
and afterwards once per year. Expert pathologists (J.N.
and S.R.) re-reviewed hematoxylin-eosin–stained slides
from all cases, and corresponding formalin-fixed,
paraffin-embedded specimens and performed the immu-
nohistochemical staining.
Immunohistochemistry
All immunohistochemical stainings were done on 5 μm
whole standard tissue sections of formaldehyde-fixed
paraffin-embedded tissue (FFPE) tumor samples (see Fig. 1).
For the detection of PD-L1 prediluted PD-L1 rabbit mono-
clonal antibody (SP263; Ventana Medical Systems, Oro Val-
ley, Arizona) was used as the primary antibody.
Immunohistochemical staining for CD8 was carried out with
an anti- CD8α mouse monoclonal antibody (C8/144B, Cell
Marque, Rocklin, California, dilution 1:50) as the primary
antibody. Both stainings were performed on a Ventana
Benchmark Ultra autostainer using the UltraView diamino-
benzidine kit (Ventana Medical Systems, Oro Valley, AZ).
Assessment of PD-L1 expression
PD-L1 expression on tumor cells was measured quanti-
tatively using an established immunohistochemistry
assay (Ventana SP 263) which had been used recently
published randomized phase III studies [8, 9, 26]. All of
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the stained sections were scored in five randomly se-
lected areas containing tumor cells, which showed mem-
branous and cytoplasmic staining. The percentage of
positive tumor cells was graded on a scale of 0–2: 0 (<
1%), 1 (1–5%); 2 (> 5%). The intensity of staining was
scored as follows: 0 (no staining), 1 (weak staining), 2
(moderate or strong staining). The H-score, ranging
from 0 to 12, was calculated by multiplying the percent-
age of positive tumor cells by the intensity of staining on
the tissue sections. The H-scores were categorized as
follows: 0: negative (−), 1–4: weak positive (+), 5–8:
moderately positive (+ +), 9–12: strong positive (+ + +).
Assessment of CD8+ TIL density
Assessment of CD8+ TIL density was performed accord-
ing to established breast cancer protocols [23]. In litera-
ture, common cut-off points ranged between 2.5 and
40% in order to differentiate between high and low
CD8+ TIL density. In our study we divided the patient
cohort in two subgroups (low and high density of CD8+
TILs: 0–40% vs. 41–100%).
Assessment of tumor immunity in the MicroEnvironment
(TIME)
Based on previous studies, four different types of tumour
immune microenvironment have been identified accord-
ing to PD-L1 expression of tumor cells and presence or
absence of TILs in the tumor microenvironment [27, 28].
These included type I (PD-L1 −with no TILs indicating
immune ignorance), type II (PD-L1 + with TILs implying
adaptive immune resistance), type III (PD-L1 −with TILs
suggesting the role of other suppressor(s) in promoting
immune tolerance) and type IV (PD-L1 +with no TILs in-
dicating intrinsic induction). All patients were stratified
according to TIME classification and TIME subgroups
were evaluated for prognostic outcome, local control, PFS
and OS.
Fig. 1 PD-L1 expression on tumor cells and CD8 expression on tumor infiltrating lymphocytes. Representative images under a microscope with a
10x enlargement of adenocarcinomas with positive (a, 80%) and negative (b, 0%) PD-L1 staining on tumor cells and adenocarcinomas with
positive (c, 70%) and negative (d, 2%) CD8 staining on tumor infiltrating lymphocytes. The arrows indicate positive (a,c) or negative (b,d) staining
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Statistical analysis
Each clinicopathologic characteristic was evaluated using
Pearson’s chi-squared test or Fisher’s exact test (categor-
ical variables). OS was measured from the date of the
initial diagnosis until the date of death. The Kaplan-
Meier method and log-rank test were applied to assess
OS. In multivariate analysis, the Cox regression propor-
tional hazard model was used to assess the clinicopatho-
logic characteristics significantly related to OS with HRs
and 95% CIs. A two-sided p value of ≤0.05 was consid-
ered statistically significant. All statistical analyses were
performed using SPSS 25 software (IBM, Armonk, NY).
Results
The clinicopathologic characteristic of all patients are
shown in Table 1. Median age was 65 years (range: 51–76
years). Histopathological biopsy was taken before treat-
ment by all patients and reviewed by pathology specialists.
Sixteen (52%) patients were diagnosed with squamous cell
carcinoma, 9 (29%) patients with adenocarcinoma and 6
(19%) with a non-specified non-small cell lung cancer.
Twenty-eight (90.3%) patients had stage III NSCLC ac-
cording to the 8th UICC TNM Staging System of lung
cancer and 3 (9.7%) patients were diagnosed with stage IV
NSCLC due to pleural involvement or malignant pleural
effusion. All 3 stage IV patients were without sensitizing
EGFR or ALK mutations. At diagnosis, 23 (74.2%) patients
were heavy smokers (median pack years (PY):40) and 8
(25.8%) patients never smokers.
All patients were treated with definitive concurrent CRT.
Twenty-five (81%) patients received platinum-based chemo-
therapy. A taxane-based combination was applied in 16
(52%) patients. Median biologically equivalent dose (EQD2)
to the primary tumor and involved nodes was 65Gy (range:
50-70Gy). Follow-up was conducted as per in-house protocol
every 3months in the first 2 years, every 6months up to 5
years and afterwards once per year.
The median overall survival in the entire patient collect-
ive was 14months (range: 3–167months). The 1-year and
2-year OS rates were 67.7 and 19.4%, respectively. The 1
and 2-year actuarial local control rates were 74 and 61%,
respectively. Median PFS, 1-year and 2-year PFS were
13 ± 1.4months, 58 and 19%, respectively.
Correlations of PD-L1 expression and clinicopathologic
characteristics
Correlations of PD-L1 expression and clinicopathologic
characteristics are shown in Table 2. PD-L1 inversely
correlates with Karnofsky performance status (p = 0.023)
and positively with CD8+ TIL density (p = 0.020).
Correlations of CD8+ TIL density and clinicopathologic
characteristics
Correlations of CD8+ TIL density and clinicopathologic
characteristics are shown in Table 3. CD8+ TIL density
inversely correlates with Karnofsky performance sta-
tus (p = 0.038) and positively with PD-L1 expression
(p = 0.020).
Prognostic impact of PD-L1 expression for local control,
PFS and OS
Univariate and multivariate analysis for OS, PFS and local
control concerning PD-L1 expression are shown in Tables 4,
Table 1 patient characteristics
Number
of patients
(%)
Age
≤ 65 years 16 (52)
> 65 years 15 (48)
Gender
Female 26 (84)
Male 5 (16)
Karnofsky performance status
> 80% 11 (35)
≤ 80% 20 (65)
UICC stage
III 28 (90)
IV 3 (10)
T category
1–2 6 (19)
3–4 25 (81)
N category
0–1 3 (10)
2–3 28 (90)
Histology
Squamous cell carcinoma 16 (52)
Non-squamous cell carcinoma 15 (48)
Tobacco consumption (PY)
0 8 (26)
20–40 8 (26)
> 40 15 (48)
Grading
Moderately differentiated 2 (6)
Poorly differentiated 27 (87)
anaplastic 2 (6)
TIME
I 10 (32)
II 5 (16)
III 5 (16)
IV 7 (23)
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5 and 6. Univariate analysis for OS showed significance (p=
0.048). However, multivariate analysis with cox regression
failed (p= 0.648). In univariate analysis for PFS and local
control, PD-L1 expression was associated with improved
PFS (p= 0.006) and improved local control rate (p= 0.017).
Prognostic impact of CD8+ TIL density for local control,
PFS and OS
Univariate and multivariate analysis for OS, PFS and
local control concerning CD8+ TIL density are shown in
Tables 4, 5 and 6. Univariate analysis showed a trend for
improved OS and better local control in patients with
low CD8+ TIL density (p = 0.055; p = 0.092).
Prognostic impact of tumor immunity in the
MicroEnvironment (TIME)
According to the Tumor Immunity in the Micro-
Environment (TIME) classification [27, 28], TIME
subgroups were evaluated for prognostic outcome for
OS, PFS and local control. The longest and shortest
OS were achieved in patients with type I (PD-L1neg/
CD8low) and type IV (PD-L1pos/CD8low) (median OS:
57 ± 37 vs. 10 ± 5 months, p = 0.05). In univariate and
multivariate analysis for OS, TIME subgroups had
significant differences (p = 0.05; p = 0.048) as well as
in univariate analysis for PFS and local control (p =
0.05; p = 0.035).
Table 2 Correlations of PD-L1 expression and clinicopathologic characteristics
Positive, n (%) Negative, n (%) p-value
Age
≤ 65 years 8 (50) 8 (50)
> 65 years 8 (57) 6 (43) 0.834
Gender
Female 13 (52) 12 (48)
Male 4 (80) 1 (20) 0.513
Karnofsky performance status
90–100% 8 (80) 2 (20)
70–80% 8 (40) 12 (60) 0.023
UICC stage
III 15 (56) 12 (44)
IV 1 (33) 2 (67) 0.447
T category
1–2 4 (67) 2 (33)
3–4 12 (50) 12 (50) 0.073
N category
0–1 2 (67) 1 (33)
2–3 14 (52) 13 (48) 0.402
Histology
Squamous cell carcinoma 9 (60) 6 (40)
Non- Squamous cell carcinoma 7 (47) 8 (53) 0.864
Tobacco consumption (PY)
0 5 (63) 3 (38)
20–40 3 (38) 5 (63)
> 40 8 (57) 6 (43) 0.105
Grading
Moderately differentiated 1 (50) 1 (50)
Poorly differentiated 14 (54) 12 (46)
anaplastic 1 (50) 1 (50) 0.223
CD8+ TILs density
≤ 40% 5 (50) 5 (50)
> 40% 10 (59) 7 (41) 0.020
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Discussion
LA-NSCLC represents a heterogeneous disease which
can include large tumor volumes, extensive lymph node
involvement and infiltration of the thoracic wall, medias-
tinum and spine [4–6]. An interdisciplinary strategy is
required to define optimal multimodal approaches based
on disease stage, patients’ general condition and treat-
ment options according to the latest evidence [29]. The
majority of these patients are inoperable due to comor-
bidities and lymph node involvement. In this situation,
multimodal treatment including concurrent application
of chemo- and radiotherapy is associated with a
moderate toxicity profile and improved patient outcome
compared to sequential CRT or radiotherapy alone [7].
Based on the results of the PACIFIC trial, consolida-
tion PD-L1 inhibition with durvalumab is currently con-
sidered as standard of care for stage III NSCLC patients
without progressive disease following platinum-based
concurrent CRT [8, 9]. In stage IV disease, patients with
initial TPS ≥ 50% can be offered pembrolizumab mono-
therapy. Stage IV patient with tumor cell PD-L1 expres-
sion < 1% and good PS can receive a combination of
platinum-based chemotherapy with PD-1 or PD-L1 in-
hibition [17–19].
Previous studies suggest that PD-L1 expression can be
a potential biomarker for efficacy of NSCLC treatment
including surgery, radiotherapy and checkpoint inhib-
ition [19, 21, 30–32]. Retrospective post-hoc analysis of
PACIFIC data suggests that outcome of patients appears
to depend on initial PD-L1 expression [9, 33].
The principal finding of our study confirms the state-
ment that initial tumor cell PD-L1 expression can be a
prognostic factor for inoperable LA-NSCLC treated with
concurrent CRT alone. In the study by Vrankar et al.,
the prognostic relevance of PD-L1 expression was evalu-
ated in 102 patients with stage III NSCLC treated with
concurrent chemoradiotherapy [30]. PD-L1 expression
≥5% on tumor cells resulted in significantly unfavorable
PFS and OS. However, several limitations of this study
need to be taken into account: only a very small patient
number (n = 7) was considered PD-L1 positive. In
addition, negative and unknown states of PD-L1 expres-
sion were evaluated together. In our study, 52% of all pa-
tients were considered PD-L1 positive according to the
cut-off value in the PACIFIC trial.
Data of the predictive value of PD-L1 expression on
tumor cells in combination with CD8+ tumor-
infiltrating lymphocyte (TIL) density in patients with lo-
cally advanced NSCLC is limited [34, 35]. Tokito et al.
found CD8+ TIL density is an independent prognostic
factor for OS [34]. Interestingly, PD-L1 expression (≥5%)
on tumor cells has shown no prognostic role in this
study in contrast to previous reports [19, 32, 36]. Indeed,
patients with low or no PD-L1 expression on tumor cells
could respond to PD-1/PD-L1 inhibition as well and
show a durable response [22, 37]. In addition, PD-L1 ex-
pression can vary between tumor cells, surrounding
non-malignant tissue and peripheral immune cells [38–
40]. Treatment modality appears to have an impact on
PD-L1 expression [41, 42]. Fujimoto et al. evaluated PD-
L1 expression on tumor cells before and after CRT and
found that alteration of PD-L1 expression was associated
with survival in patients with LA-NSCLC [42].
As a result, the interaction of tumor and immune cells
in the treatment and immune response is still poorly
understood. Based on preclinical and clinical data, the
Table 3 Correlations of CD8+ TILs density and clinicopathologic
characteristics
high, n (%) low, n (%) p-value
Age
≤ 65 years 12 (80) 3 (20)
> 65 years 6 (46) 7 (54) 0.403
Gender
Female 14 (61) 9 (39)
Male 4 (80) 1 (20) 0.384
Karnofsky performance status
> 80% 9 (90) 1 (10)
≤ 80% 9 (50) 9 (50) 0.038
UICC stage
III 17 (65) 9 (35)
IV 1 (50) 1 (50) 0.409
T category
1–2 3 (60) 2 (40)
3–4 15 (65) 8 (35) 0.751
N category
0–1 2 (67) 1 (33)
2–3 16 (64) 9 (36) 0.899
Histology
Squamous cell carcinoma 8 (62) 5 (39)
Non- Squamous cell carcinoma 10 (67) 5 (33) 0.681
Tobacco consumption (PY)
0 6 (75) 2 (25)
20–40 5 (71) 2 (29)
> 40 7 (54) 6 (46) 0.11
Grading
Moderately differentiated 0 (0) 2 (100)
Poorly differentiated 16 (67) 8 (33)
anaplastic 2 (100) 0 (0) 0.067
PD-L1 expression
0% 7 (58) 5 (42)
≥ 1% 10 (67) 5 (33) 0.02
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Table 4 univariate and multivariate survival analysis
Survival p-value
at 12 months (%) at 24 months (%) univariate Analysis multivariate Analysis
Age
≤ 65 years 56 19
> 65 years 80 27 0.676
Gender
Female 80 20
Male 65 23 0.629
Karnofsky performance status
> 80% 75 30
≤ 80% 55 10 0.041 0.077
UICC stage
III 64 21
IV 100 33 0.537
T category
1–2 67 0
3–4 68 28 0.395
N category
0–1 33 0
2–3 71 25 0.299
Histology
Squamous cell carcinoma 69 25
Non- Squamous cell carcinoma 67 20 0.935
Tobacco consumption (PY)
0 75 25
20–40 50 12,50
> 40 73 27 0.758
Grading
Moderately differentiated 50 50
Poorly differentiated 67 19
anaplastic 100 50 0.758
PD-L1 expression
0% 86 29
≥ 1% 50 19 0.048 0.648
CD8+ TILs density
≤ 40% 70 40
> 40% 61 17 0.055
TIME type
I 100 60
II 50 20
III 71 14
IV 40 20 0.05 0.048
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Table 5 univariate and multivariate analysis of local control
Local control p-value
at
12 months (%)
at
24 months (%)
univariate
Analysis
multivariate
Analysis
Age
65 years 58 58
> 65 years 83 63 0.380
Gender
Female 68 57
Male 80 80 0.941
Karnofsky performance status
> 80% 73 67
≤ 80% 66 33 0.233
UICC stage
III 66 62
IV 100 67 0.862
T category
1–2 66 62
3–4 100 67 0.970
N category
0–1 33 33
2–3 75 64 0.154
Histology
Squamous cell carcinoma 70 60
Non- Squamous cell carcinoma 70 62 0.766
Tobacco consumption (PY)
0 83 83
20–40 51 34
> 40 72 60 0.417
Grading
Moderately differentiated 100 100
Poorly differentiated 70 59
anaplastic 50 50 0.487
PD-L1 expression
0% 92 79
≥ 1% 44 44 0.017 0.045
CD8+ TILs density
≤ 40% 86 75
> 40% 62 62 0.092
TIME type
I 100 80
II 41 41
III 83 83
IV 67 67 0.05 0.694
Gennen et al. Radiation Oncology            (2020) 15:5 Page 8 of 12
Table 6 univariate and multivariate analysis of progression free survival (PFS)
PFS P-value
at
12 months (%)
at
24 months (%)
univariate
Analysis
multivariate
Analysis
Age
≤ 65 years 50 19
> 65 years 67 20 0.925
Gender
Female 80 20
Male 54 19 0.868
Karnofsky performance status
> 80% 65 25
≤ 80% 46 9 0.134
UICC stage
III 54 18
IV 100 33 0.458
T category
1–2 67 0
3–4 56 20 0.292
N category
0–1 33 0
2–3 61 20 0.235
Histology
Squamous cell carcinoma 56 19
Non- Squamous cell carcinoma 60 20 0.855
Tobacco consumption (PY)
0 63 25
20–40 38 13
> 40 67 20 0.633
Grading
Moderately differentiated 50 50
Poorly differentiated 59 15
anaplastic 50 50 0.831
PD-L1 expression
0% 86 29
≥ 1% 31 13 0.006 0.061
CD8+ TILs density
≤ 40% 70 30
> 40% 50 17 0.201
TIME type
I 100 60
II 30 20
III 71 14
IV 40 0 0.035 0.144
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involvement of CD8+ TILs plays a crucial role in tumor-
associated immune response [43]. The CD8+ TIL dens-
ity in the tumor microenvironment has been suggested
to predict the oncologic outcome in different cancer
types such as colorectal cancer, malignant melanoma
and anal cancer [28, 44, 45]. Based on previous studies,
four different types of tumor immune microenvironment
have been identified according to PD-L1 expression of
tumor cells and presence or absence of TILs in the
tumor microenvironment. These included type I (PD-
L1neg with no TILs indicating immune ignorance), type
II (PD-L1pos with TILs implying adaptive immune resist-
ance, type III (PD-L1neg with TILs suggesting a role of
other suppressor(s) in promoting immune tolerance)
and type IV (PD-L1pos with no TILs indicating intrinsic
induction). In our study, the longest OS was achieved in
patients with type I (PD-L1neg/CD8low) in contrast to
previous studies investigating the prognostic value of
PD-L1 expression combined with CD8+ TIL density. In
the studies of Tokito et al. and El-Guindy et al., patients
with PD-L1neg/CD8high had the longest OS and accord-
ing to Yang et al. the patient subgroup with PD-L1pos/
CD8high showed the longest OS [34, 35, 46]].
The shortest OS in our study was seen in patients with
type IV (PD-L1pos/CD8low) and well in accordance with
the published literature [33, 34, 45]. This finding could be
explained by the lack of immune-mediated tumor re-
sponse. Tumor cells can decrease their immunogenicity
through interaction of PD-L1 with PD-1 on T cells. As a
result, the tumor can evade the immune surveillance. In
addition, a lack of CD8+ TILs can account for most non-
responders to PD-1/PD-L1 inhibition [28].
Several limitations of this study need to be considered
when interpreting the results. Firstly, the retrospective
nature of this study and the possibility of unknown
biases. Secondly, the relatively small number of patients
included in the analysis and lastly, all patients were
treated at a single center. However, we are convinced
that our findings supporting the assessment of CD8+
TIL density combined with PD-L1 expression, instead of
PD-L1 expression alone is of important clinical relevance
and requires special consideration in future trials.
Conclusion
Initial PD-L1 expression on tumor cells can be a
prognostic factor for local control, PFS and OS and
correlates with CD8+ TILs density in inoperable
LA-NSCLC. Assessment of PD-L1 expression in
combination with CD8+ TILs density, instead of PD-
L1 expression alone, appears to be of strong prog-
nostic relevance in patients treated with concurrent
CRT. Future prospective studies are warranted to
verify our findings.
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